Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Ibrutinib (Primary)
- Indications CNS cancer
- Focus Therapeutic Use
- 05 Oct 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
- 05 Oct 2016 Status changed from not yet recruiting to recruiting.
- 10 Dec 2015 New trial record